Mr. Sun joins Hepalink from Yunfeng Capital, one of the largest China-based private equity funds, where he served as Managing Director responsible for global healthcare investment. Prior to Yunfeng, Mr. Sun worked at UBS AG, and served as Managing Director and Head of Asia Healthcare Investment Banking. Previously, he was a pharmaceutical sector equity research analyst with Morgan Stanley based in New York, and a research scientist at Bristol-Myers Squibb.
https://www.marketscreener.com/SHENZHEN-HEPALINK-PHARMAC-6914250/news/Shenzhen-Hepalink-Pharmaceutical-Hepalink-Announces-the-Appointment-of-Healthcare-Senior-Executive-30117734/
You are welcome.